Citing a “growing global consensus” against the use of product-specific suffixes to non-proprietary names to distinguish biosimilar medicines from their brand biologic counterparts, the International Generic and Biosimilar medicines Association (IGBA) has called on the US Food and Drug Administration (FDA) to rethink its use of such a mechanism given its status as a “notable outlier”.
The call follows Health Canada’s recent decision to not add suffixes to non-proprietary names for biologics – including biosimilars – leaving the US as the only major territory to operate such a convention
